Navigation Links
Chiasma to Present at the UBS Global Life Sciences Conference
Date:9/20/2010

NEW YORK and JERUSALEM, Sept. 21 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, announced that Fredric Price, Chiasma's Chairman & CEO, will present an overview of the Company at the UBS Global Life Sciences Conference at the Grand Hyatt, New York, New York, on Wednesday, September 22, 2010 at 11:00 AM (ET).

Chiasma is currently conducting its second clinical trial of the investigational new drug Octreolin™, an oral form of octreotide acetate that uses the proprietary Transient Permeability Enhancer (TPE) system for the oral treatment of acromegaly, a hormonal disorder that results from an excess of growth hormone.  A third clinical trial is planned to start by the end of 2010. The Food and Drug Administration has granted orphan drug designation for Octreolin and the Company will submit an application for Orphan Medicinal Product Designation to the European Medicines Agency (EMA) shortly.

Upon receipt of positive Phase 3 efficacy and safety data, the Company will submit an NDA using the "505(b)(2) regulatory pathway" in the United States and its equivalent, the "Hybrid Application," in Europe.

Chiasma is also developing Octreolin as a potential treatment for patients with portal hypertension (PHT); there are currently no drugs approved for PHT in the U.S.

About Chiasma

Chiasma is evaluating the TPE technology with approved drugs, which may enable their being switched from injectable to oral, and potentially may also result in new indications or otherwise improved labels.  The TPE technology promotes the delivery of drugs to the GI wall and from there to the liver.  It is applicable to macromolecules that, to date, can be administered only by injection.  TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.  The Company has successfully demonstrated proof-of-principle in delivering small proteins, peptides, saccharides and heretofore-insoluble small molecules via the oral route.

The Company is backed by ARCH Venture Partners, MPM Capital, F2 Ventures, 7 Health Ventures and the MPM Novartis Strategic Fund. Chiasma is a Delaware corporation with a 100% owned Israeli subsidiary. Additional information can be found at:  www.ChiasmaPharma.com.

Forward-Looking Statements

This press release contains forward-looking statements about the business, goals and prospects of Chiasma, Inc., including, without limitation, statements about the development of drugs in the TPE system.  These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements.  Chiasma is under no obligation, and expressly disclaims any obligation, to update or alter any forward-looking statement, whether as a result of new information, future events o otherwise.


'/>"/>
SOURCE Chiasma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chiasma Receives Orphan Drug Designation From the FDA for Octreolin™ for the Oral Treatment of Acromegaly
2. Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study
3. Seahorse Bioscience to Present at 2010 UBS Global Life Sciences Conference
4. Caliper Life Sciences CEO to Present Keynote Presentation at MipTec European Conference
5. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
6. Cardium to Present at 10th Annual Biotech in Europe Investor Forum
7. Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City
8. CryoLife to Present at UBS Global Life Sciences Conference
9. Sigma-Aldrich to Present at the UBS Global Life Sciences Healthcare Conference on Tuesday, September 21, 2010
10. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
11. BioSpecifics Technologies Corp. to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
Breaking Biology News(10 mins):